MRNA Jan 2025 60.000 call
| Previous close | 51.37 |
| Open | 51.37 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 60.00 |
| Expiry date | 2025-01-17 |
| Day's range | 51.37 - 51.37 |
| Contract range | N/A |
| Volume | |
| Open interest | 148 |
- Yahoo Finance Video
Apple, Novo Nordisk earnings, jobless claims: What to watch
A number of companies release their quarterly earning reports on Thursday, including Apple (AAPL), Novo Nordisk (NVO), Shell (SHEL), ConocoPhillips (COP), Cigna (CI), Coinbase (COIN), Moderna (MRNA), DraftKings (DKNG), Kellanova (K), United States Steel (X), and more. On the economic front, jobless claims for the week ending on April 27 will be released. Economists expect claims to rise to 212,000 from 207,000 the prior week. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Nicholas Jacobino
GuruFocus.comModerna Inc (MRNA) Q1 2024 Earnings: Significant Revenue Decline Amid Strategic Shifts
Comparative Analysis of Q1 Financials Against Analyst Expectations
ReutersModerna posts quarterly sales beat, smaller loss than expected
(Reuters) -Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came in dramatically lower than the previous year when demand for COVID-19 vaccines was higher. Sales of Moderna’s COVID-19 shot Spikevax, its only marketed product, dropped 91% from the previous year to $167 million for the quarter but surpassed analysts’ expectations of $97.5 million. The Cambridge, Massachusetts-based company reaffirmed that it expects to receive approval from regulators for its respiratory syncytial virus (RSV) vaccine in time for it to be included in this fall's U.S. vaccine campaign.
